These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 33471186)

  • 21. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer.
    Franzese C; Zucali PA; Di Brina L; D'Agostino G; Navarria P; Franceschini D; Santoro A; Scorsetti M
    Cancer Med; 2018 Sep; 7(9):4379-4386. PubMed ID: 30073758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease.
    Osti MF; Agolli L; Valeriani M; Reverberi C; Bracci S; Marinelli L; De Sanctis V; Cortesi E; Martelli M; De Dominicis C; Minniti G; Nicosia L
    Lung Cancer; 2018 Aug; 122():165-170. PubMed ID: 30032826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
    Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
    Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
    Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis.
    Franzese C; Nicosia L; Facondo G; Lo Faro L; Cuccia F; Vullo G; Osti MF; Alongi F; Scorsetti M
    Clin Exp Metastasis; 2021 Dec; 38(6):511-518. PubMed ID: 34651241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
    Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
    Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival, Treatment Outcome, and Safety of Multiple and Repeated Courses of Stereotactic Body Radiotherapy for Pulmonary Oligometastases of Head and Neck Squamous Cell Carcinoma.
    Vorbach SM; Mangesius J; Dejaco D; Seppi T; Santer M; Zur Nedden S; Sarcletti MP; Pointner MJ; Hart TJ; Riechelmann H; Ganswindt U; Nevinny-Stickel M
    Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer.
    Scorsetti M; Franceschini D; De Rose F; Comito T; Villa E; Iftode C; Navarria P; D'Agostino GR; Masci G; Torrisi R; Testori A; Tinterri C; Santoro A
    Breast; 2016 Apr; 26():11-7. PubMed ID: 27017237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group.
    Franzese C; Ingargiola R; Tomatis S; Iacovelli NA; Beltramo G; Franco P; Bonomo P; Zanetti IB; Argenone A; Cante D; Romanello DA; Musio D; De Felice F; Furlan C; Scorsetti M; Orlandi E
    Oral Dis; 2022 Mar; 28(2):345-351. PubMed ID: 33320410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
    Salim N; Tumanova K; Popodko A; Libson E
    JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
    Yeung R; Hamm J; Liu M; Schellenberg D
    Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
    Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
    Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
    Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
    Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
    Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
    Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
    Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
    Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions.
    Milano MT; Katz AW; Muhs AG; Philip A; Buchholz DJ; Schell MC; Okunieff P
    Cancer; 2008 Feb; 112(3):650-8. PubMed ID: 18072260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.